Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

3.9K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
3.9K
Exercise and Cardiac Output01:17

Exercise and Cardiac Output

1.8K
Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be...
1.8K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

323
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

438
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
438
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026
Same author

Thick filament molecular interfaces play a critical role in the pathogenesis of hypertrophic cardiomyopathy.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
Same author

Chasing the Genetic Landscape Beyond the Pulmonary Veins.

JACC. Advances·2026
Same author

A Common <i>CD36</i> Variant and the Genetic Landscape of Dilated Cardiomyopathy in Individuals of African Ancestry.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jan 12, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.2K

Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers.

Ezimamaka Ajufo1,2, Shinwan Kany1,3, Sean J Jurgens1,4

  • 1Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

JAMA Cardiology
|November 8, 2025
PubMed
Summary

Moderate to vigorous physical activity (MVPA) is safe and beneficial for individuals with genetic cardiomyopathy variants without symptoms. Exercise is linked to reduced cardiovascular risks and similar cardiac remodeling compared to non-carriers, supporting guideline recommendations.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans
07:26

Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans

Published on: October 17, 2018

21.2K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.2K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans
07:26

Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans

Published on: October 17, 2018

21.2K

Area of Science:

  • Cardiology
  • Genetics
  • Preventive Medicine

Background:

  • Individuals with genetic cardiomyopathies may face risks with exercise.
  • The impact of physical activity on asymptomatic carriers of cardiomyopathy-associated variants (G+P-) is not well understood.

Purpose of the Study:

  • To investigate if moderate to vigorous physical activity (MVPA) affects cardiovascular outcomes, cardiac structure, and the risk of developing cardiomyopathy or ventricular arrhythmias differently in G+P- carriers versus non-carriers.

Main Methods:

  • Utilized UK Biobank data from 84,699 participants with whole-genome sequencing and accelerometer-measured physical activity.
  • Followed participants for a median of 8 years, analyzing associations between MVPA and cardiovascular outcomes, cardiac remodeling via CMR, and clinical cardiomyopathy onset.
  • Compared outcomes between G+P- carriers and non-carriers.

Main Results:

  • Higher MVPA was associated with lower cardiovascular disease risk in G+P- carriers, irrespective of genotype.
  • MVPA between 100-400 minutes/week showed the lowest risk for G+P- carriers.
  • Cardiac remodeling was similar between G+P- carriers and non-carriers with increasing MVPA.
  • Higher MVPA correlated with a lower risk of incident cardiomyopathy and no increased risk of ventricular arrhythmias in G+P- carriers.

Conclusions:

  • Moderate to vigorous physical activity, within guideline recommendations, is associated with reduced adverse cardiovascular outcomes and similar cardiac remodeling in G+P- carriers compared to non-carriers.
  • These findings support current physical activity guidelines for individuals carrying cardiomyopathy-associated variants.